Everads Therapy
Tel Aviv, Israel· Est.
Platform company delivering suprachoroidal injections to improve retinal disease treatments.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Platform company delivering suprachoroidal injections to improve retinal disease treatments.
Ophthalmology
Technology Platform
A proprietary suprachoroidal injector that creates a tangential, non‑sharp entry into the suprachoroidal space, enabling high‑volume, large‑particle delivery to the retina and choroid.
Opportunities
Growing demand for efficient posterior‑segment delivery of gene and cell therapies; potential licensing deals with pharma partners seeking suprachoroidal administration.
Risk Factors
Regulatory uncertainty for combination device‑drug products; technical challenges in scaling injector manufacturing; competition from other suprachoroidal platforms.
Competitive Landscape
Few companies offer suprachoroidal delivery (e.g., Clearside, Ocular Therapeutix); Everads differentiates through high‑volume capacity, large‑particle tolerance, and compatibility with standard syringes.